Alexion Pharm Inc (ALXN) 123.98 $ALXN Biotech S
Post# of 273322
Posted On: 09/02/2016 1:23:43 PM
Alexion Pharm Inc (ALXN) 123.98 $ALXN
Biotech Stock Roundup: Gilead in Patent Infringement Lawsuit, Enbrel Biosimilar Approved
Arpita Dutt - Zacks Investment Research - Thu Sep 01, 9:54AM CDT
The overall healthcare sector was under pressure with focus going back to the pricing policies of pharma and biotech companies.
GILD: 76.95 (-0.47), ALXN: 123.98 (-1.65), MYL: 40.35 (-1.57), AMGN: 169.23 (-0.90), ARIA: 10.06 (-0.13), RIGL: 3.37 (-0.08), REGN: 387.89 (-5.51)
After Yesterday's Decline of 1.73%, Alexion Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Wed Aug 31, 2:13PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $125.69 to a high of $128.72. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $127.28 on volume of 465,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ALXN: 123.98 (-1.65)
Biotech Stocks on Investors' Radar -- Alexion Pharma, BioMarin Pharma, Merrimack Pharma, and Pacific Biosciences of California
PR Newswire - Wed Aug 31, 6:50AM CDT
Stock-Callers.com's focus shifted to Biotechnology industry which uses biological systems or living organisms for the development of biopharmaceutical drugs. Two main catalysts driving stocks in this arena are clinical and regulatory developments. Let us now review today's featured companies: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), and Pacific Biosciences of California Inc. (NASDAQ: PACB). Learn more about these stocks by downloading their comprehensive and free reports at:
MACK: 4.54 (-0.05), PACB: 8.21 (-0.09), BMRN: 95.75 (+0.56), ALXN: 123.98 (-1.65)
Alexion's GVHD Candidate Gets Orphan Drug Status in the EU
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 9:04AM CDT
Alexion Pharmaceuticals' (ALXN) ALXN1007 received orphan drug designation in the EU for the treatment of graft-versus-host disease.
ANIP: 60.17 (-1.25), GERN: 2.75 (+0.02), ALXN: 123.98 (-1.65), ANIK: 47.73 (-0.21)
European Commission Grants Orphan Drug Designation to ALXN1007 for the Treatment of Patients with Graft-Versus-Host Disease (GVHD)
BusinessWire - Mon Aug 29, 3:33PM CDT
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the European Commission has granted orphan drug designation (ODD) to ALXN1007, a novel anti-inflammatory monoclonal antibody targeting complement protein C5a, for the treatment of graft-versus-host disease (GVHD). Alexion is currently investigating ALXN1007 in patients with acute GVHD of the lower gastrointestinal tract (GI-GVHD), a severe and life-threatening rare autoimmune disease that can occur as a complication of stem cell or bone marrow transplantation.(1,2,3)
ALXN: 123.98 (-1.65)
Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review
Arpita Dutt - Zacks Investment Research - Wed Aug 24, 1:09PM CDT
Acquisitions are back in focus in the biotech sector with Medivation (MDVN) agreeing to be acquired by Pfizer for $14 billion.
MDVN: 80.87 (-0.06), BIIB: 312.79 (+6.76), PTLA: 20.76 (-0.10), CLVS: 23.16 (-0.43), GILD: 76.95 (-0.47), ALXN: 123.98 (-1.65), REGN: 387.89 (-5.51)
After Yesterday's Rally of 3.12% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Aug 22, 1:30PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $133.06 to a high of $136.26. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $134.43 on volume of 524,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALXN: 123.98 (-1.65)
New Strong Sell Stocks for August 22nd
Zacks Equity Research - Zacks Investment Research - Mon Aug 22, 8:33AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Monday
SYT: 88.12 (+0.44), HSNI: 42.02 (+0.06), ALXN: 123.98 (-1.65), CBT: 50.44 (+0.41), WAGE: 63.70 (+0.92)
Alexion Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 2.44%
Comtex SmarTrend(R) - Mon Aug 15, 2:19PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $133.83 to a high of $136.70. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $135.49 on volume of 630,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALXN: 123.98 (-1.65)
New Strong Sell Stocks for August 15th
Zacks Equity Research - Zacks Investment Research - Mon Aug 15, 6:37AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Monday
ACHC: 51.27 (+0.94), ABAX: 49.96 (-0.44), ARCB: 18.65 (+0.18), AV: 11.65 (+0.09), ALXN: 123.98 (-1.65)
Exxon Mobil and SolarCity skid; Caesars advances
AP - Mon Aug 01, 4:08PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Monday:
PN: 8.88 (+0.20), ALXN: 123.98 (-1.65), CZR: 6.26 (+0.03), FLTX: 59.87 (-0.02), IONS: 29.84 (-0.20), FDC: 14.34 (+0.41)
Look for Shares of Alexion Pharmaceuticals to Potentially Pullback after Yesterday's 3.06% Rise
Comtex SmarTrend(R) - Mon Aug 01, 12:23PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $128.76 to a high of $135.14. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $135.00 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALXN: 123.98 (-1.65)
After Yesterday's Rally of 1.96% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Jul 28, 12:10PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $130.00 to a high of $135.00. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $130.32 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALXN: 123.98 (-1.65)
Alexion (ALXN) Tops Q2 Earnings and Revenues (Revised)
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 10:33AM CDT
Alexion's (ALXN) second-quarter 2016 earnings of 93 cents per share surpassed the Zacks Consensus Estimate of 91 cents.
INVA: 11.01 (-0.06), ANIP: 60.17 (-1.25), ALXN: 123.98 (-1.65), NKTR: 18.27 (+0.16)
Alexion (ALXN) Beats on Q2 Earnings and Revenues
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 7:15AM CDT
Alexion (ALXN) reported earnings of 92 cents in the second-quarter of 2016, with revenues coming in at $753 million.
ALXN: 123.98 (-1.65)
Alexion Reports Second Quarter 2016 Results
BusinessWire - Thu Jul 28, 5:30AM CDT
--- Soliris(R) (eculizumab) Revenue Growth Driven by Steady Number of New Patients with PNH and aHUS Treated Globally -
ALXN: 123.98 (-1.65)
Biotech Stock Roundup: Biogen Q2 Results Impress, Gilead HCV Franchise Under Pressure
Arpita Dutt - Zacks Investment Research - Wed Jul 27, 2:25PM CDT
With the second quarter earnings season in full swing, several biotech companies including Amgen (AMGN) will be reporting this week.
BIIB: 312.79 (+6.76), VRTX: 94.69 (-0.06), GILD: 76.95 (-0.47), ALXN: 123.98 (-1.65), AMGN: 169.23 (-0.90), ABBV: 64.02 (-0.01), CELG: 105.46 (-0.91)
Biotech Stock Roundup: Gilead in Patent Infringement Lawsuit, Enbrel Biosimilar Approved
Arpita Dutt - Zacks Investment Research - Thu Sep 01, 9:54AM CDT
The overall healthcare sector was under pressure with focus going back to the pricing policies of pharma and biotech companies.
GILD: 76.95 (-0.47), ALXN: 123.98 (-1.65), MYL: 40.35 (-1.57), AMGN: 169.23 (-0.90), ARIA: 10.06 (-0.13), RIGL: 3.37 (-0.08), REGN: 387.89 (-5.51)
After Yesterday's Decline of 1.73%, Alexion Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Wed Aug 31, 2:13PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $125.69 to a high of $128.72. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $127.28 on volume of 465,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ALXN: 123.98 (-1.65)
Biotech Stocks on Investors' Radar -- Alexion Pharma, BioMarin Pharma, Merrimack Pharma, and Pacific Biosciences of California
PR Newswire - Wed Aug 31, 6:50AM CDT
Stock-Callers.com's focus shifted to Biotechnology industry which uses biological systems or living organisms for the development of biopharmaceutical drugs. Two main catalysts driving stocks in this arena are clinical and regulatory developments. Let us now review today's featured companies: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), and Pacific Biosciences of California Inc. (NASDAQ: PACB). Learn more about these stocks by downloading their comprehensive and free reports at:
MACK: 4.54 (-0.05), PACB: 8.21 (-0.09), BMRN: 95.75 (+0.56), ALXN: 123.98 (-1.65)
Alexion's GVHD Candidate Gets Orphan Drug Status in the EU
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 9:04AM CDT
Alexion Pharmaceuticals' (ALXN) ALXN1007 received orphan drug designation in the EU for the treatment of graft-versus-host disease.
ANIP: 60.17 (-1.25), GERN: 2.75 (+0.02), ALXN: 123.98 (-1.65), ANIK: 47.73 (-0.21)
European Commission Grants Orphan Drug Designation to ALXN1007 for the Treatment of Patients with Graft-Versus-Host Disease (GVHD)
BusinessWire - Mon Aug 29, 3:33PM CDT
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the European Commission has granted orphan drug designation (ODD) to ALXN1007, a novel anti-inflammatory monoclonal antibody targeting complement protein C5a, for the treatment of graft-versus-host disease (GVHD). Alexion is currently investigating ALXN1007 in patients with acute GVHD of the lower gastrointestinal tract (GI-GVHD), a severe and life-threatening rare autoimmune disease that can occur as a complication of stem cell or bone marrow transplantation.(1,2,3)
ALXN: 123.98 (-1.65)
Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review
Arpita Dutt - Zacks Investment Research - Wed Aug 24, 1:09PM CDT
Acquisitions are back in focus in the biotech sector with Medivation (MDVN) agreeing to be acquired by Pfizer for $14 billion.
MDVN: 80.87 (-0.06), BIIB: 312.79 (+6.76), PTLA: 20.76 (-0.10), CLVS: 23.16 (-0.43), GILD: 76.95 (-0.47), ALXN: 123.98 (-1.65), REGN: 387.89 (-5.51)
After Yesterday's Rally of 3.12% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Aug 22, 1:30PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $133.06 to a high of $136.26. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $134.43 on volume of 524,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALXN: 123.98 (-1.65)
New Strong Sell Stocks for August 22nd
Zacks Equity Research - Zacks Investment Research - Mon Aug 22, 8:33AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Monday
SYT: 88.12 (+0.44), HSNI: 42.02 (+0.06), ALXN: 123.98 (-1.65), CBT: 50.44 (+0.41), WAGE: 63.70 (+0.92)
Alexion Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 2.44%
Comtex SmarTrend(R) - Mon Aug 15, 2:19PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $133.83 to a high of $136.70. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $135.49 on volume of 630,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALXN: 123.98 (-1.65)
New Strong Sell Stocks for August 15th
Zacks Equity Research - Zacks Investment Research - Mon Aug 15, 6:37AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Monday
ACHC: 51.27 (+0.94), ABAX: 49.96 (-0.44), ARCB: 18.65 (+0.18), AV: 11.65 (+0.09), ALXN: 123.98 (-1.65)
Exxon Mobil and SolarCity skid; Caesars advances
AP - Mon Aug 01, 4:08PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Monday:
PN: 8.88 (+0.20), ALXN: 123.98 (-1.65), CZR: 6.26 (+0.03), FLTX: 59.87 (-0.02), IONS: 29.84 (-0.20), FDC: 14.34 (+0.41)
Look for Shares of Alexion Pharmaceuticals to Potentially Pullback after Yesterday's 3.06% Rise
Comtex SmarTrend(R) - Mon Aug 01, 12:23PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $128.76 to a high of $135.14. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $135.00 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALXN: 123.98 (-1.65)
After Yesterday's Rally of 1.96% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Jul 28, 12:10PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $130.00 to a high of $135.00. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $130.32 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALXN: 123.98 (-1.65)
Alexion (ALXN) Tops Q2 Earnings and Revenues (Revised)
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 10:33AM CDT
Alexion's (ALXN) second-quarter 2016 earnings of 93 cents per share surpassed the Zacks Consensus Estimate of 91 cents.
INVA: 11.01 (-0.06), ANIP: 60.17 (-1.25), ALXN: 123.98 (-1.65), NKTR: 18.27 (+0.16)
Alexion (ALXN) Beats on Q2 Earnings and Revenues
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 7:15AM CDT
Alexion (ALXN) reported earnings of 92 cents in the second-quarter of 2016, with revenues coming in at $753 million.
ALXN: 123.98 (-1.65)
Alexion Reports Second Quarter 2016 Results
BusinessWire - Thu Jul 28, 5:30AM CDT
--- Soliris(R) (eculizumab) Revenue Growth Driven by Steady Number of New Patients with PNH and aHUS Treated Globally -
ALXN: 123.98 (-1.65)
Biotech Stock Roundup: Biogen Q2 Results Impress, Gilead HCV Franchise Under Pressure
Arpita Dutt - Zacks Investment Research - Wed Jul 27, 2:25PM CDT
With the second quarter earnings season in full swing, several biotech companies including Amgen (AMGN) will be reporting this week.
BIIB: 312.79 (+6.76), VRTX: 94.69 (-0.06), GILD: 76.95 (-0.47), ALXN: 123.98 (-1.65), AMGN: 169.23 (-0.90), ABBV: 64.02 (-0.01), CELG: 105.46 (-0.91)
(0)
(0)